CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies
CervoMed to Appoint William Elder as Chief Financial Officer [Yahoo! Finance]
CervoMed to Appoint William Elder as Chief Financial Officer
CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates
CervoMed Inc. (NASDAQ: CRVO) had its price target raised by analysts at Canaccord Genuity Group Inc. from $50.00 to $65.00. They now have a "buy" rating on the stock.